Case report
A 45-year-old patient presented to the emergency department with a seven-day history of polyuria, polydipsia and vomiting, and drowsiness that developed on the day of admission. There was no past medical or drug history and the patient had lived in the UK for years.
The patient' s observations were as follows: the heart rate was 128 beats/minute, blood pressure 140/65 mm Hg, respiratory rate 36/min, and temperature 36°C. On examination, the Glasgow Coma Score (GCS) was 12/15; there was propotosis with conjugate gaze palsy, but otherwise the physical examination was normal. ECG revealed inferolateral ST elevation with reciprocal ST depression in leads V1-V4. The haemoglobin was 7.6 g/dL, mean cell volume 67 fL, sodium 120 mmol/L and creatinine 128 µmol/L. A venous blood gas showed a pH of 6.79, pCO 2 2.0 kPa, pO 2 4.47 kPa, HCO 3 -2.8 mmol/L, base excess -29.6 mmol/L and glucose 36.8 mmol/L. Urine dipstick showed 2+ glucose, 4+ ketones, 3+ blood and 3+ protein.
The initial diagnosis was of new-onset diabetes mellitus, presenting with ketoacidosis, and probable new-onset myocardial ischaemia. Treatment was commenced with 0.9% saline, insulin and potassium infusions. On review by a cardiologist, an evolving acute coronary syndrome was suspected, and a tirofibran infusion and fondaparinux were started, a loading dose of aspirin given and the patient transferred to the intensive care unit for invasive monitoring and further management.
During the next 24 hours, the patient remained persistently hyperglycaemic, despite receiving up to 15 units/hr of insulin. Intravenous fluids continued, initially with 0.9% saline, but Hartmann' s solution was substituted to avoid hyperchloraemic acidosis. Subsequently, serum sodium concentrations rose, so fluids were changed to 0.45% sodium chloride and then 5% dextrose. Nevertheless, the sodium levels continued to rise, to 172 mmol/L, 36 hours after admission. Throughout this period, the patient was polyuric, with urine output up to 500 mL/hr. This was initially considered to be due to the osmotic effect of ongoing, resistant hyperglycaemia. Despite attempts to prevent hyperchloraemic acidosis, the chloride level reached 155 mmol/L, with a strong ion difference of 21 meq/L (normal approximately 40 meq/L). The patient gradually became more obtunded (lowest GCS 6), requiring intubation.
The troponin I level was 0.06 µg/L (normal <0.05 µg/mL), creatinine kinase 199 iu/L (normal 30-210 iu/L). Trans-thoracic echocardiography showed no regional wall-motion abnormalities. On re-assessment, the cardiology team felt that it was unlikely that the ECG changes reflected an acute coronary syndrome, and anti-platelet medication was withdrawn after 48 hours of treatment. The ECG normalised over the subsequent two days.
On the day following admission, the case was discussed with the patient' s relatives. During this meeting, the patient' s identical twin was introduced, and a striking difference in their appearance noted. Re-examination of the patient, in the presence of the twin, highlighted the presence of macroglossia, coarse facies and enlarged hands, the extent of which had not been appreciated previously. On this basis, a clinical diagnosis of acromegaly was made.
It was suspected that a pituitary growth-hormone-secreting macroadenoma was causing posterior pituitary dysfunction, with diabetes insipidus accounting for persistent polyuria and rapidly increasing plasma sodium concentration. The presence of a pituitary tumour was confirmed by contrast-enhanced CT imaging which demonstrated an enlarged pituitary sella, with a non-enhancing soft tissue mass extending beyond the sella, consistent with pituitary macroadenoma (Figures 1 and 2) . The
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A patient presenting with diabetic ketoacidosis and diabetes insipidus was found to have acromegaly. This is an unusual presentation of a rare condition and highlights the need for broad diagnostic skills in intensive care medicine in order to institute effective treatment. Diabetic ketoacidosis is a common reason for admission to hospital and is associated with increased morbidity and mortality. It is likely that an increasing proportion of patients will be admitted to intensive care in view of current guidelines for the management of severe diabetic ketoacidosis. One of the secondary causes of diabetes is acromegaly. This is a rare condition, often associated with a delay from the onset of symptoms to diagnosis, and diabetes is an uncommon presentation. This patient presented with features of both diabetes mellitus and diabetes insipidus, both associated with acromegaly.
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urine osmolality was 233 mOsm/kg with serum osmolality 366 mOsm/kg (normal 280-300 mOsm/kg), consistent with the diagnosis of diabetes insipidus. Serum insulin-like growth factor-1 (IGF-1) level was raised at 47.7 nmol/L (normal 15.2-44.7 nmol/L).
The patient was commenced on desmopressin, and reviewed by the endocrinology team who recommended starting octreotide and pegvisomant in addition to desmopressin.
The following day, magnetic resonance imaging (MRI) of the brain (Figure 3) showed evidence of haemorrhagic transformation, with the optic chiasm displaced by the tumour. In view of the risk to vision from compression at the optic chiasm and probable expansion and bleeding within the pituitary tumour (pituitary apoplexy), the patient was transferred to theatre for urgent trans-sphenoidal hypophysectomy. At surgery, a necrotic cystic tumour was found and debulked. The procedure was uneventful despite the earlier potent anti-platelet therapy. Pegvisomant was stopped following the resection.
Hypernatraemia gradually resolved and plasma glucose concentrations became well controlled with insulin. The patient made a good recovery and was discharged seven days later from ICU. Subsequent MRI follow-up revealed a persistently expanded pituitary fossa with a small rim of residual pituitary tissue and a stable residuum of tumour.
At the most recent clinic attendance, the patient remained well, with normal visual fields, and the acromegaly was controlled (IGF-1 11.9 nmol/L) on no medical treatment. Insulin therapy was stopped in hospital and the patient was discharged on metformin, which has since stopped.
Discussion
Acromegaly is a rare condition with an annual incidence of 3-4 cases per million population. It is most commonly caused by a benign pituitary adenoma that causes chronic growth hormone (GH) hypersecretion. The effects of GH are mediated via insulin-like growth factor-1 (IGF-1) produced largely in the liver. This leads to the characteristic coarse facial features, soft tissue hypertrophy, and spade-like hands and feet, as well as other multi-system pathology, which includes hypertension, secondary diabetes and cardiomyopathy. The diagnosis of acromegaly is made using both clinical and biochemical evidence. Clinically, the diagnosis is usually made several years after the onset of symptoms, with acral changes and headaches the most common presenting complaints. In a series of 100 patients from Massachusetts, the diagnosis was usually made in primary care, not intensive care. 1 Diabetes was present in 15% of the patients at presentation, but diabetes as the initial complaint was uncommon, representing 1% of the total.
Case reports
Diabetes in acromegaly is due to peripheral insulin resistance, mediated by multiple different pathways, and may explain why this patient failed to respond to high-dose insulin therapy. The need for high-dose insulin has been noted previously. 2 Failure to respond to conventional treatment should trigger consideration of secondary causes of diabetes in patients with diabetic ketoacidosis (DKA). 3 Hyponatraemia is a common electrolyte disturbance in hospitalised patients and is associated with an increased mortality. 4 This is usually hypotonic hyponatraemia with low plasma osmolality. In DKA however, there is hypertonic hyponatraemia due to the osmotic activity of glucose attracting water from the intracellular compartment into the intravascular space. Attempts have been made to adjust the measured sodium concentration to allow for hyperglycaemia, with correction factors ranging from 1.6-2.4 mmol/L for every 100 mg/dL (≡5.6 mmol/L) increase in glucose concentration above the normal range. 5, 6 With a blood sugar of 36.8 mmol/L, the patient' s sodium concentration on admission would have been approximately 129-133.5 mmol/L rather than the measured 120 mmol/L.
The rate of correction of hyponatraemia should not exceed 0.5 mmol/L/hr due to the risk of central pontine myelinolysis with more rapid correction. In this case, the sodium concentration increased from 120 mmol/L to 172 mmol/L in 36 hours, a mean rate of change of 1.44 mmol/L/hr. Fortunately, there were no neurological sequelae as a consequence. Overly rapid correction can be a particularly difficult problem to manage in the hypovolaemic patient and warrants judicious use of sodium-and glucose-containing fluids.
Despite the initial hyponatraemia, this patient rapidly developed hypernatraemia. Hypernatraemia is predominantly caused by a relative loss of water. In this instance, it was initially assumed that the osmotic diuretic effect of continuing glycosuria was responsible for high water losses and that the reduced conscious level was masking thirst and preventing water ingestion, leading to progressive hypernatraemia. Only when the diagnosis of acromegaly with diabetes inspidus was made was the significance of the persistent polyuria and hypernatraemia fully explained.
Diabetes inspidus (DI) is divided into cranial and nephrogenic subtypes, with cranial DI a well-recognised complication of neurosurgery; other causes include tumours, trauma, ischaemia, infiltrative diseases and idiopathic. The classic clinical triad of polyuria, polydipsia and nocturia is not seen in sedated patients, where behavioural changes to increase water intake cannot be observed and excessive water loss causes hypernatraemia. The diagnosis of DI requires raised serum osmolality (>295 mOsm/kg) with inappropriately dilute urine (urine osmolality <700 mOsmol/kg) as was seen in this case. Treatment of DI depends on the underlying diagnosis and the severity of illness, but in the acute state the vasopressin analogue, desmopressin is used. Desmopressin (1-desamino-8-Darginine vasopressin) has a more specific and longer duration of action on V 2 receptors with less vasopressor response.
In uncomplicated acromegaly, the principle aim of treatment is to achieve normal basal GH and IGF-1 levels (biochemical control) as this has been shown to reduce the increased mortality associated with the disease. 7 Initial treatment for the majority of patients is surgical, by transsphenoidal tumour resection. This offers rapid reduction in GH levels with biochemical control in 75-95% of patients with intrasellar microadenomas and in 40-68% of noninvasive macroadenomas. 8 For those patients who do not achieve biochemical control with surgery or for whom surgery is contraindicated, drug treatment is necessary.
The specific treatment of this patient' s acromegaly was both pharmacological and surgical. The main rationale for requesting neurosurgical decompression was the perceived threat of visual loss both from the size of the tumour and from possible pituitary haemorrhage (pituitary apoplexy). Until the MRI, medical treatment was favoured to control growth hormone levels using the somatostatin analogue octreotide to reduce GH secretion, and pegvisomant, a pegylated GH-like peptide, which acts as a GH receptor antagonist.
Pituitary apoplexy is characterised by sudden onset of headache, visual disturbances (including visual loss, visual field defects, and ocular paresis), haemodynamic changes, vomiting and altered level of consciousness. Although our patient' s depressed conscious level was attributed to hypernatraemia, sudden pituitary ischaemia with subsequent haemorrhage could also have contributed, and a gaze palsy was noted at presentation (cranial nerves III, IV and V are vulnerable to compression within the cavernous sinus). Management of pituitary apoplexy involves frequent careful neurological and visual assessments, together with steroid replacement in those patients with low blood pressure. Medical management is indicated in patients without neuroophthalmic signs, 9 but where there is actual visual loss, surgery is indicated. Due to our inability to assess visual acuity in the intubated and sedated patient, the haemorrhagic transformation of the tumour, and the likely pre-existing ocular paresis, surgery was undertaken, accepting that prior aspirin administration increased the risk of postoperative complications, specifically haemorrhage. 10
Summary
This case posed several problems in both diagnosis and management, and fulfils the principle of diagnostic parsimony known as Ockham' s razor. Initially, the problem appeared to be DKA that failed to respond to standard treatment. Persistent hyperglycaemia could have accounted for uncontrolled water loss, and the development of hypernatraemia. However, only when the unifying diagnosis of acromegaly was made, with the recognition that insulin therapy alone would not correct hyperglycaemia and that posterior pituitary dysfunction and DI were contributing to the hypernatraemia, could correct treatments be instituted.
Patient consent
Verbal consent from the patient for publication of this report has been documented; however, written consent was unobtainable due to the patient not attending for follow-up. In view of this, details of this case have been altered in order to protect the identification of the patient.
